Hsiao-Ling Hung, PhD, RAC(洪筱玲博士)

North America Regulatory Leader in Oncology
Director, Global Regulatory Affairs
Janssen Pharmaceutical Companies of Johnson & Johnson







Dr. Hsiao-Ling is Hung a North America Regulatory Leader in Oncology at Janssen Pharmaceutical Companies of Johnson & Johnson. She leads the North America regulatory strategy for 3 oncology products in early and late phase development. She is leveraging her past experience in cancer research and biomarkers to contribute to the development of expedited clinical programs and companion diagnostics for targeted therapies.

Prior to a career in regulatory affairs, Dr. Hung was a bench scientist for over 20 years. At Genaera Corporation, a biopharmaceutical company, she led the discovery and preclinical research programs of compounds across multiple therapeutic areas including oncology, ophthalmology, metabolic disease and respiratory disease. Before industry, she was a post-doctoral fellow at University of Pennsylvania, investigating chromatin modification in hematopoiesis.

Dr. Hung received a BS in Medical Technology from National Taiwan University and a PhD in Pathology and Molecular Biology from University of Pennsylvania.